Comparative Pharmacology
Head-to-head clinical analysis: FEMSTAT 3 versus MONISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMSTAT 3 versus MONISTAT.
FEMSTAT 3 vs MONISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butoconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing ergosterol synthesis and disrupting fungal cell membrane integrity.
Miconazole, the active ingredient in MONISTAT, inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity, leading to cell death.
Intravaginal cream: 1 applicatorful (5 g of 2% butoconazole nitrate) intravaginally at bedtime for 3 consecutive days.
Intravaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 2% cream 5 g intravaginally at bedtime for 7 days. Topical: Apply 2% cream twice daily for 2-4 weeks.
None Documented
None Documented
The terminal elimination half-life of butoconazole following topical vaginal administration is approximately 21-24 hours. This prolonged half-life supports once-daily dosing for 3 days in the treatment of vulvovaginal candidiasis.
Approximately 90-120 minutes; supports twice-daily local dosing.
Following topical vaginal administration of butoconazole nitrate, approximately 5% of the dose is absorbed systemically. The absorbed fraction is primarily metabolized in the liver and excreted via the biliary/fecal route. Renal excretion accounts for less than 3% of the administered dose.
Primarily fecal (approximately 90%) as unchanged drug; less than 2% renal elimination.
Category C
Category C
Antifungal
Antifungal